{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"10"}],"units":"Participants"}],"description":"Number of participants with greater than 75% BTK occupancy of zanubrutinib in peripheral blood mononuclear cells (PBMCs)","groups":[{"description":"Participants received 40 mg of zanubrutinib once daily (QD) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up","id":"OG000","title":"Part 1: 40 mg QD"},{"description":"Participants received 80 mg of zanubrutinib once daily (QD) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up","id":"OG001","title":"Part 1: 80 mg QD"},{"description":"Participants received 160 mg of zanubrutinib once daily (QD) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up","id":"OG002","title":"Part 1: 160 mg QD"},{"description":"Part 1: Participants received 160 mg of zanubrutinib twice daily (BID) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up were evaluated. Part 2: This dose regimen was selected for further evaluation in various expansion cohorts that span multiple disease types.","id":"OG003","title":"Part 1 and Part 2: 160 mg BID"},{"description":"Part 1: Participants received 320 mg of zanubrutinib once daily (QD) orally until disease progression, intolerance or death, withdrawal of consent, or loss to follow-up were evaluated. Part 2: This dose regimen was selected for further evaluation in various expansion cohorts that span multiple disease types.","id":"OG004","title":"Part 1 and Part 2: 320 mg QD"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Pharmacodynamic analysis set consisted of participants in which PBMCs were collected and evaluable samples were obtained.","reportingStatus":"POSTED","timeFrame":"Week 1 Day 1 (W1D1) predose, W1D1 4 hours, W1D2 24 hours, W1D3 predose, and W2D1 predose","title":"Number of Participants With Greater Than 75% Bruton's Tyrosine Kinase (BTK) Occupancy","type":"SECONDARY","unitOfMeasure":"Participants"}